2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…2016 American Transplant Congress
Survival Benefit of Living Donor ABOi Kidney Transplantation.
A recent editorial in AJT characterized ABOi transplants as "Twice as Expensive, Half as Good" and challenged the ABOi community to evaluate survival benefit of…2016 American Transplant Congress
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).
Introduction: Highly-HLA sensitized patients are at risk for developing donor specific antibodies (DSA) & ABMR post-transplant (tx). However, incidence and risk of acute rejections (AR)…2016 American Transplant Congress
RNAseq Transcriptome Analysis of Bone Marrow CD138+ Plasma Cell Responses to Carfilzomib Monotherapy Desensitization.
Medicine, Surgery, Biomedical Informatics, U of Cincinnati, Cincinnati Children's, Cincinnati, OH.
Purpose: Prior studies indicate that bone marrow resident plasma cells (BMRPCs) demonstrate varying sensitivity to proteasome inhibition (PI). Effects of carfilzomib (CFZ) monotherapy desensitization on…2016 American Transplant Congress
Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization.
University of Cincinnati, Cincinnati.
Background. Desensitization results have largely focused on effects on anti-HLA antibody (HLA-Ab) and anti-ABO antibody levels. Anti-angiotensin II type 1 receptor antibody (AT1R-Ab) has recently…2016 American Transplant Congress
Survival Benefit of DCD Livers.
Liver transplantation benefits registrants with MELD≥18. However, this benefit no doubt varies by donor characteristics, and the benefit of DCD livers remains unclear.Methods: We used…2016 American Transplant Congress
Impact of Proximity MELD/PELD Points on Liver Redistricting Scenarios.
Background: To address geographic disparity in liver allocation, a new organ distribution system consisting of 4 or 8 districts has been proposed (Gentry, Am J…2016 American Transplant Congress
Skipping Comparable Local Waitlist Candidates Under Share 35.
1Surgery, Johns Hopkins University, Baltimore, MD; 2Mathematics, US Naval Academy, Annapolis, MD.
Under Share-35, deceased donor (DD) livers are offered regionally to candidates with MELD≥35 before locally to lower MELD candidates. The characteristics and outcomes of local…2016 American Transplant Congress
What Are the Charges and Costs of Transplanting High MELD Patients?
Transplant Surgery, NYU Langone Medical Center, New York, NY.
Purpose: There is a significant variation in the MELD scores and subsequent morbidity among liver recipients in the US. Larger OPOs consistently serve patients with…
American Transplant Congress abstracts